Could a common antibiotic tame severe asthma in kids?

NCT ID NCT06223828

Recruiting now Disease control Sponsor: Johns Hopkins All Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This study tests whether azithromycin, an antibiotic, can reduce airway inflammation in children ages 3-17 hospitalized for critical asthma. One hundred participants will receive the drug for three days while researchers monitor inflammation markers and side effects. The goal is to see if this treatment can shorten ICU stays and improve recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: azithromycin (an antibiotic that may also reduce inflammation)
What this could lead to: If it works, this could offer a short, safe treatment to help children recover faster from severe asthma attacks and reduce time in the ICU.
What could go wrong: This is an early-phase, open-label study with no placebo group, so results may be less reliable. Azithromycin can cause side effects like stomach upset or heart rhythm changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRITICAL ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute asthma childhood onset asthma Critical Illness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRITICAL ILLNESS PEDIATRIC ASTHMA

Contacts and locations

Locations

Johns Hopkins All Children's Hospital
RECRUITING

St. Petersburg, Florida, 33701, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.